00:00Cardiovascular diseases have always been considered as exclusive men's diseases, but in reality
00:10they are the main cause of death for women.
00:13Even 46% of the deaths in women's lupus are due to cardiovascular causes, against 38%
00:22in men.
00:23So, women are highly involved in this, and what is the cause of such a high mortality rate?
00:31Probably, it is also an underestimation by women, but also by doctors, of the symptoms
00:38that are linked to these diseases.
00:41Just think of the classic example of myocardial infarction, which is classically manifested
00:47in men, with pain in the left arm, while in women the symptoms are often much more
00:53blurred, they are intestinal pain, nausea, great tiredness, and very often a woman
00:58finds herself going to the emergency room with these very severe disorders and is recovered
01:03in a gastroenterology department, and this clearly translates into a delay in
01:08diagnosis, a delay in therapy, and therefore a higher mortality rate.
01:13Therefore, it is absolutely necessary to train, to update the health personnel to make
01:21the health personnel aware of the differences, also in terms of clinical manifestations,
01:27the symptomatology of these diseases in men and women, but it is also very important
01:32a communication, a dissemination to the population, so that everyone can be aware,
01:38everyone must be aware of their health needs, also due to the peculiarities of
01:44sex and gender, and certainly also in terms of drugs, these differences are very important,
01:50we know that drugs have normally been tested, they have been analyzed on a male body,
01:56even when women are enrolled, then the data is not analyzed, the results are not
02:03disaggregated by sex, and therefore the differences are not highlighted,
02:07neither in terms of tolerability, nor in terms of the effectiveness of the drug.
02:12Therefore, all these things must be analyzed, all these aspects must be included,
02:17it must be considered that medicine for men and medicine for women are separate,
02:22they are different, they must be considered both in order to achieve equity and
02:27the ownership of the cures in a truly effective way.
02:30In Italy there was a law, the law 3 of 2018, which was a bit, it makes us a little bit
02:37the first of the class, also in Europe, because we have this law in which Article 3
02:44ensures the consideration of a certain gender in clinical trials, in research,
02:50in training, in communication, but despite this, we still have to make a big effort,
02:56we also have to make big investments, because all these laws are anyway at zero cost,
03:02and without money, without the possibility of investing, it is clearly very difficult to reach
03:08even the experiments that are balanced for men and for women, because clearly
03:13to achieve statistical significance you have to double the numbers.
03:18So on the one hand it would seem a much greater expense, at least initially,
03:22even if then the savings are evident, because we consider that many drugs that have been
03:27removed from the market, have been removed from the market precisely because they gave
03:31significant adverse effects in the female sex.
Comments